Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAN1012 + toripalimab
- Development stage
- Unknown
- Lead developer
- Canwell Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CAN1012 + toripalimab is an investigational combination therapy comprising CAN1012, a novel immune checkpoint inhibitor under development by Canwell Biotech, administered together with toripalimab, an approved humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1). CAN1012's exact molecular target and detailed mechanism are not disclosed in the provided data, but it is evaluated in combination with toripalimab to enhance immunotherapeutic strategies in oncology. Toripalimab blocks PD-1 on T cells, inhibiting the PD-1/PD-L1 interaction to restore anti-tumor immune activity. This combination is currently being evaluated in early-phase clinical studies for safety and pharmacodynamic effects[1]. Primary indications include solid tumors, likely focusing on cancers with immunotherapy potential.
- Other names
- CAN1012 + toripalimab
02
Targets
TLR7 (Toll-like receptor 7)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CAN1012 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAN1012 + toripalimab.